» Articles » PMID: 36875308

DNA Mismatch Repair System Imbalances in Breast Adenocarcinoma

Abstract

DNA mismatch repair system (MMR) is considered a leading genetic mechanism in stabilizing DNA structure and maintaining its function. DNA MMR is a highly conserved system in bacteria, prokaryotic, and eukaryotic cells, and provides the highest protection to DNA by repairing micro-structural alterations. DNA MMR proteins are involved in the detection and repair of intra-nucleotide base-to-base errors inside the complementary DNA strand recognizing the recently synthesized strand from the parental template. During DNA replication, a spectrum of errors including base insertion, deletion, and miss-incorporation negatively affect the molecule's structure and its functional stability. A broad spectrum of genomic alterations such as promoter hyper methylation, mutation, and loss of heterozygosity (LOH) in MMR genes including predominantly hMLH1, hMSH2, hMSH3, hMSH6, hPMS1, and hPMS2 lead to their loss of base-to-base error repairing procedure. Microsatellite instability (MSI) refers to the DNA MMR gene alterations that are observed in a variety of malignancies of different histological origins. In the current review, we present the role of DNA MMR deficiency in breast adenocarcinoma, a leading cancer-based cause of death in females worldwide.

Citing Articles

Molecular Basis of Breast Tumor Heterogeneity.

Dikoglu E, Pareja F Adv Exp Med Biol. 2025; 1464():237-257.

PMID: 39821029 DOI: 10.1007/978-3-031-70875-6_13.


Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application.

Su L, Bu J, Yu J, Jin M, Meng G, Zhu X Clin Transl Med. 2024; 14(11):e70066.

PMID: 39462685 PMC: 11513202. DOI: 10.1002/ctm2.70066.


DNA Methylation-Based Diagnosis and Treatment of Breast Cancer.

Peng X, Zheng J, Liu T, Zhou Z, Song C, Zhang D Curr Cancer Drug Targets. 2024; 25(1):26-37.

PMID: 38441008 DOI: 10.2174/0115680096278978240204162353.

References
1.
Lira D, Teodoro T, Pinhal M, Affonso Fonseca F, Gehrke F, Azzalis L . Profile of hMSH2 expression in breast tumors and lymph nodes: a preliminary study. Eur Rev Med Pharmacol Sci. 2015; 19(17):3229-33. View

2.
Ma F, Laster K, Dong Z . The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. Nat Commun. 2022; 13(1):5651. PMC: 9512793. DOI: 10.1038/s41467-022-33351-4. View

3.
Win A, Lindor N, Jenkins M . Risk of breast cancer in Lynch syndrome: a systematic review. Breast Cancer Res. 2013; 15(2):R27. PMC: 3672741. DOI: 10.1186/bcr3405. View

4.
Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

5.
Malik S, Zia A, Mubarik S, Masood N, Rashid S, Sherrard A . Correlation of MLH1 polymorphisms, survival statistics, in silico assessment and gene downregulation with clinical outcomes among breast cancer cases. Mol Biol Rep. 2019; 47(1):683-692. DOI: 10.1007/s11033-019-05175-x. View